M-Vizion Femoral Revision System Extension
Medacta International S.A. · Decision date Sep 17, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 17, 2026 for K260173, a Traditional 510(k) from Medacta International S.A. for the M-Vizion Femoral Revision System Extension, classified under product code LZO with secondary codes KWY and KWZ in the orthopedic specialty. SE denotes 510(k) clearance, not premarket approval. The submission describes a range extension to the M-Vizion Monoblock (K212327) and M-Vizion Femoral Revision System (K191816, K170690) and to the MectaCer Biolox Delta Heads (K112115).
The changed items are M-Vizion Monoblock Stem small sizes (diameter 10 to 11), M-Vizion Distal Stem straight small sizes (diameter 10 to 11), M-Vizion Distal Stem curved, and MectaCer Biolox Delta Head size 22.2 M. The summary states equivalence to the listed predicates across indications, design, fixation, materials, biocompatibility, usage, packaging, shelf-life and sterility, with the range of product as the stated difference, supported by design validation and fatigue testing. The summary excerpt ends mid-list of non-clinical studies, so the full test set is not established here.
The source does not state a clinical rationale for the added sizes beyond covering a wider population, and no post-market or comparative clinical outcomes are reported. The decision letter is addressed to Christopher Lussier at Medacta USA, while the 510(k) summary names Stefano Baj as contact person; the public notification lists a receipt date of January 21, 2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 17, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260173
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Medacta International S.A.
- Product code
- LZO
- Decision code
- SESE
- Decision date
- Sep 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented.
- Applicant
- Medacta International S.A.
- Product code
- LZO
- FDA device class
- 2
FDA decision timeline
K260173 received
Application receipt date recorded by FDA.
K260173 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LZO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NEXUS Hip StemK262473 | Microport Orthopedics, Inc. | 510(k) clearance | Oct 1, 2026 | FDA |
| United Orthopedic Corporation | 510(k) clearance | Sep 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medacta International S.A.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Castel San Pietro
Sources and methodology
- Original FDA record: K260173
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
